4.6 Article

Improved structural variant interpretation for hereditary cancer susceptibility using long-read sequencing

期刊

GENETICS IN MEDICINE
卷 -, 期 -, 页码 -

出版社

ELSEVIER SCIENCE INC
DOI: 10.1038/s41436-020-0880-8

关键词

hereditary cancer; variant interpretation; structural variants; genome sequencing; long-read sequencing

资金

  1. Genome Canada
  2. Genome BC [202SEQ, 212SEQ, 12002]
  3. Canada Foundation for Innovation [20070, 30198, 30981, 33408]
  4. BC Knowledge Development Fund
  5. BC Cancer Foundation
  6. Genome British Columbia [B20POG]
  7. University of British Columbia Clinician Investigator Program
  8. Canadian Institutes for Health Research Postdoctoral Fellowship award
  9. Canadian Institutes of Health Research
  10. Michael Smith Foundation for Health Research

向作者/读者索取更多资源

Purpose Structural variants (SVs) may be an underestimated cause of hereditary cancer syndromes given the current limitations of short-read next-generation sequencing. Here we investigated the utility of long-read sequencing in resolving germline SVs in cancer susceptibility genes detected through short-read genome sequencing. Methods Known or suspected deleterious germline SVs were identified using Illumina genome sequencing across a cohort of 669 advanced cancer patients with paired tumor genome and transcriptome sequencing. Candidate SVs were subsequently assessed by Oxford Nanopore long-read sequencing. Results Nanopore sequencing confirmed eight simple pathogenic or likely pathogenic SVs, resolving three additional variants whose impact could not be fully elucidated through short-read sequencing. A recurrent sequencing artifact on chromosome 16p13 and one complex rearrangement on chromosome 5q35 were subsequently classified as likely benign, obviating the need for further clinical assessment. Variant configuration was further resolved in one case with a complex pathogenic rearrangement affectingTSC2. Conclusion Our findings demonstrate that long-read sequencing can improve the validation, resolution, and classification of germline SVs. This has important implications for return of results, cascade carrier testing, cancer screening, and prophylactic interventions.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Clinical Neurology

Amplification of the PLAG-family genes-PLAGL1 and PLAGL2-is a key feature of the novel tumor type CNS embryonal tumor with PLAGL amplification

Michaela-Kristina Keck, Martin Sill, Andrea Wittmann, Piyush Joshi, Damian Stichel, Pengbo Beck, Konstantin Okonechnikow, Philipp Sievers, Annika K. Wefers, Federico Roncaroli, Shivaram Avula, Martin G. McCabe, James T. Hayden, Pieter Wesseling, Ingrid Ora, Monica Nister, Mariette E. G. Kranendonk, Bastiaan B. J. Tops, Michal Zapotocky, Josef Zamecnik, Alexandre Vasiljevic, Tanguy Fenouil, David Meyronet, Katja von Hoff, Ulrich Schuller, Hugues Loiseau, Dominique Figarella-Branger, Christof M. Kramm, Dominik Sturm, David Scheie, Tuomas Rauramaa, Jouni Pesola, Johannes Gojo, Christine Haberler, Sebastian Brandner, Tom Jacques, Alexandra Sexton Oates, Richard Saffery, Ewa Koscielniak, Suzanne J. Baker, Stephen Yip, Matija Snuderl, Nasir Ud Din, David Samuel, Kathrin Schramm, Mirjam Blattner-Johnson, Florian Selt, Jonas Ecker, Till Milde, Andreas von Deimling, Andrey Korshunov, Arie Perry, Stefan M. Pfister, Felix Sahm, David A. Solomon, David T. W. Jones

Summary: Pediatric central nervous system (CNS) tumors are the leading cause of cancer-related death in children aged 0-14 years. A newly identified CNS tumor type characterized by PLAGL1/2 amplification and a lack of recurrent genetic alterations has been described. These tumors are composed of primitive embryonal-like cells and are associated with intermediate survival, but the cell of origin and optimal treatment strategies are yet to be determined.

ACTA NEUROPATHOLOGICA (2023)

Article Biotechnology & Applied Microbiology

NCBP2 and TFRC are novel prognostic biomarkers in oral squamous cell carcinoma

Rahul Arora, Logan Haynes, Mehul Kumar, Reid McNeil, Jahanshah Ashkani, Steven C. Nakoneshny, T. Wayne Matthews, Shamir Chandarana, Robert D. Hart, Steven J. M. Jones, Joseph C. Dort, Doha Itani, Ayan Chanda, Pinaki Bose

Summary: There is a lack of prognostic biomarkers and targeted therapeutics for oral squamous cell carcinoma (OSCC). However, amplification of the chromosomal segment 3q22-3q29 is observed in many epithelial cancers, including OSCC. Through an integrative analysis, we identified NCBP2 and TFRC as potential prognostic biomarkers for HPV-negative OSCC, and showed that NCBP2 depletion can inhibit OSCC cell proliferation, migration, and invasion.

CANCER GENE THERAPY (2023)

Article Biochemistry & Molecular Biology

CIViCdb 2022: evolution of an open-access cancer variant interpretation knowledgebase

Kilannin Krysiak, Arpad M. Danos, Jason Saliba, Joshua F. McMichael, Adam C. Coffman, Susanna Kiwala, Erica K. Barnell, Lana Sheta, Cameron J. Grisdale, Lynzey Kujan, Shahil Pema, Jake Lever, Sarah Ridd, Nicholas C. Spies, Veronica Andric, Andreea Chiorean, Damian T. Rieke, Kaitlin A. Clark, Caralyn Reisle, Ajay C. Venigalla, Mark Evans, Payal Jani, Hideaki Takahashi, Avila Suda, Peter Horak, Deborah Ritter, Xin Zhou, Benjamin J. Ainscough, Sean Delong, Chimene Kesserwan, Mario Lamping, Haolin Shen, Alex R. Marr, My H. Hoang, Kartik Singhal, Mariam Khanfar, Brian Li, Wan-Hsin Lin, Panieh Terraf, Laura B. Corson, Yasser Salama, Katie M. Campbell, Kirsten M. Farncombe, Jianling Ji, Xiaonan Zhao, Xinjie Xu, Rashmi Kanagal-Shamanna, Ian King, Kelsy C. Cotto, Zachary L. Skidmore, Jason R. Walker, Jinghui Zhang, Aleksandar Milosavljevic, Ronak Y. Patel, Rachel H. Giles, Raymond H. Kim, Lynn M. Schriml, Elaine R. Mardis, Steven J. M. Jones, Gordana Raca, Shruti Rao, Subha Madhavan, Alex H. Wagner, Malachi Griffith, Obi L. Griffith

Summary: CIVIC is a crowd-sourced, public domain knowledgebase that provides literature-derived evidence characterizing the clinical utility of cancer variants. It supports variant interpretation guidelines, increases interoperability with other variant resources, and promotes widespread dissemination of structured curated data. It currently includes over 300 contributors and represents >3200 variants in >470 genes from >3100 publications.

NUCLEIC ACIDS RESEARCH (2023)

Article Biochemistry & Molecular Biology

Defining the heterogeneity of unbalanced structural variation underlying breast cancer susceptibility by nanopore genome sequencing

Katherine Dixon, Yaoqing Shen, Kieran O'Neill, Karen L. L. Mungall, Simon Chan, Steve Bilobram, Wei Zhang, Marjorie Bezeau, Alshanee Sharma, Alexandra Fok, Andrew J. J. Mungall, Richard Moore, Ian Bosdet, My Linh Thibodeau, Sophie Sun, Stephen Yip, Kasmintan A. A. Schrader, Steven J. M. Jones

Summary: Nanopore long-read sequencing accurately detects pathogenic copy number alterations in cancer susceptibility genes and reveals unforeseen allelic heterogeneity and mechanisms of recurrent deletions. Integrating read-based and statistical phasing helps define extended haplotypes associated with founder alleles. Long-read sequencing is a sensitive method for characterizing private, recurrent and founder structural variants underlying breast cancer susceptibility.

EUROPEAN JOURNAL OF HUMAN GENETICS (2023)

Article Biochemistry & Molecular Biology

Immune Activation following Irbesartan Treatment in a Colorectal Cancer Patient: A Case Study

E. Titmuss, K. Milne, M. R. Jones, T. Ng, J. T. Topham, S. D. Brown, D. F. Schaeffer, S. Kalloger, D. Wilson, R. D. Corbett, L. M. Williamson, K. Mungall, A. J. Mungall, R. A. Holt, B. H. Nelson, S. J. M. Jones, J. Laskin, H. J. Lim, M. A. Marra

Summary: The POG program at BC Cancer identified specific alterations in colorectal cancer using whole genome and transcriptome analysis, and successfully treated a patient with irbesartan, an antihypertensive drug, resulting in a profound and durable response. Analysis showed an increase in immune signaling and infiltrating immune cells, particularly CD8+ T cells, in the relapsed tumor, suggesting an activated immune response contributed to the anti-tumor effect.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Multidisciplinary Sciences

macroH2A2 antagonizes epigenetic programs of stemness in glioblastoma

Ana Nikolic, Francesca Maule, Anna Bobyn, Katrina Ellestad, Seungil Paik, Sajid A. Marhon, Parinaz Mehdipour, Xueqing Lun, Huey-Miin Chen, Claire Mallard, Alexander J. Hay, Michael J. Johnston, Christopher J. Gafuik, Franz J. Zemp, Yaoqing Shen, Nicoletta Ninkovic, Katalin Osz, Elodie Labit, N. Daniel Berger, Duncan K. Brownsey, John J. Kelly, Jeff Biernaskie, Peter B. Dirks, Darren J. Derksen, Steven J. M. Jones, Donna L. Senger, Jennifer A. Chan, Douglas J. Mahoney, Daniel D. De Carvalho, Marco Gallo

Summary: The histone variant macroH2A2 controls an epigenetic mechanism of self-renewal and suggests new treatment approaches for glioblastoma patients.

NATURE COMMUNICATIONS (2023)

Article Genetics & Heredity

Population-size history inferences from the coho salmon (Oncorhynchus kisutch) genome

Eric B. Rondeau, Kris A. Christensen, David R. Minkley, Jong S. Leong, Michelle T. T. Chan, Cody A. Despins, Anita Mueller, Dionne Sakhrani, Carlo A. Biagi, Quentin Rougemont, Eric Normandeau, Steven J. M. Jones, Robert H. Devlin, Ruth E. Withler, Terry D. Beacham, Kerry A. Naish, Jose M. Yanez, Roberto Neira, Louis Bernatchez, William S. Davidson, Ben F. Koop

Summary: The coho salmon populations in North America have significantly declined, and analysis of genomic data suggests bottleneck events after glacial retreat as a possible cause. A chromosome-level genome assembly and genome resequencing of 83 coho salmon were performed to aid in stock management and conservation efforts.

G3-GENES GENOMES GENETICS (2023)

Article Oncology

Homologous recombination deficiency signatures in gastrointestinal and thoracic cancers correlate with platinum therapy duration

Erica S. S. Tsang, Veronika Csizmok, Laura M. M. Williamson, Erin Pleasance, James T. T. Topham, Joanna M. M. Karasinska, Emma Titmuss, Intan Schrader, Stephen Yip, Basile Tessier-Cloutier, Karen Mungall, Tony Ng, Sophie Sun, Howard J. J. Lim, Jonathan M. M. Loree, Janessa Laskin, Marco A. A. Marra, Steven J. M. Jones, David F. F. Schaeffer, Daniel J. J. Renouf

Summary: Emerging evidence suggests a predictive role of homologous recombination deficiency (HRD) in gastrointestinal and thoracic malignancies. In this study, whole genome and transcriptomic data were reviewed to evaluate HRD scores and single base substitution 3 (SBS3) in advanced GI and thoracic cancers. The association between HRD and time to progression on platinum (TTPp) was examined, and it was found that SBS3 was more strongly associated with TTPp in GI malignancies. Tumors with gBRCA1/2 mutations and a somatic second alteration showed high SBS3 and HRD scores, indicating potential therapeutic targets.

NPJ PRECISION ONCOLOGY (2023)

Article Oncology

A generalizable machine learning framework for classifying DNA repair defects using ctDNA exomes

Elie J. Ritch, Cameron Herberts, Evan W. Warner, Sarah W. S. Ng, Edmond M. Kwan, Jack V. W. Bacon, Cecily Q. Bernales, Elena Schonlau, Nicolette M. Fonseca, Veda N. Giri, Corinne Maurice-Dror, Gillian Vandekerkhove, Steven J. M. Jones, Kim N. N. Chi, Alexander W. Wyatt

Summary: Specific classes of DNA damage repair defects can increase sensitivity to emerging therapies for metastatic prostate cancer. However, biomarker approaches based on DDR gene sequencing are not accurate predictors of DDR deficiency or treatment efficacy. We developed a machine learning approach using whole-exome sequencing data to simultaneously identify multiple types of DDR deficiencies in metastatic prostate cancer.

NPJ PRECISION ONCOLOGY (2023)

Article Genetics & Heredity

HostSeq: a Canadian whole genome sequencing and clinical data resource

S. Yoo, E. Garg, L. T. Elliott, R. J. Hung, A. R. Halevy, J. D. Brooks, S. B. Bull, F. Gagnon, C. M. T. Greenwood, J. F. Lawless, A. D. Paterson, L. Sun, M. H. Zawati, J. Lerner-Ellis, R. J. S. Abraham, I Birol, G. Bourque, J-m Garant, C. Gosselin, J. Li, J. Whitney, B. Thiruvahindrapuram, J-a Herbrick, M. Lorenti, M. S. Reuter, O. O. Adeoye, S. Liu, U. Allen, F. P. Bernier, C. M. Biggs, A. M. Cheung, J. Cowan, M. Herridge, D. M. Maslove, B. P. Modi, V Mooser, S. K. Morris, M. Ostrowski, R. S. Parekh, G. Pfeffer, O. Suchowersky, J. Taher, J. Upton, R. L. Warren, R. S. M. Yeung, N. Aziz, S. E. Turvey, B. M. Knoppers, M. Lathrop, S. J. M. Jones, S. W. Scherer, L. J. Strug

Summary: HostSeq was launched in April 2020 to integrate whole genome sequencing data and clinical information of 10,000 Canadians infected with SARS-CoV-2. It aims to support research communities in understanding disease risk factors and developing interventions. HostSeq is a collaboration among 13 epidemiological studies across five provinces in Canada, providing aggregated data through two portals and individual-level data for global health research.

BMC GENOMIC DATA (2023)

Review Clinical Neurology

Malignant transformation of adult-onset pilocytic astrocytoma to diffuse leptomeningeal glioneuronal tumor within the thoracic spine: a case report and review of the literature

Pedram Laghaei Farimani, Alexander D. D. Rebchuk, Stephano J. J. Chang, Stephen Yip, Cynthia Hawkins, Tamir T. T. Ailon

Summary: We report a case of a 31-year-old male with progressive myelopathy due to thoracic pilocytic astrocytoma (PA) that transformed into diffuse leptomeningeal glioneuronal tumor (DLGNT) with high-grade features. Our case is the first reported adult-onset spinal PA malignant transformation to DLGNT. This highlights the need for novel management approaches and contributes to the limited clinical data on such transformations.

ACTA NEUROCHIRURGICA (2023)

Article Oncology

Disparate Time-to-Treatment and Varied Incidence of Actionable Non-Small Cell Lung Cancer Molecular Alterations in British Columbia: A Historical Cohort Study

Roy Avraham Hilzenrat, Stephen Yip, Barbara Melosky, Cheryl Ho, Janessa Laskin, Sophie Sun, James J. Choi, Anna L. McGuire

Summary: The outcomes for early-stage NSCLC are not satisfactory despite advances in systemic therapy. The BC lung cancer screening program aims to identify NSCLC patients at different stages. Understanding the molecular epidemiology and treatment initiation time across various regions in BC is crucial to optimize care for NSCLC. The study found that actionable driver mutations were present in all regions, but there were disparities in the time to initiate treatment.

CURRENT ONCOLOGY (2023)

Article Cell Biology

Parent-of-origin detection and chromosome-scale haplotyping using long-read DNA methylation sequencing and Strand-seq

Vahid Akbari, Vincent C. T. Hanlon, Kieran O'Neill, Louis Lefebvre, Kasmintan A. Schrader, Peter M. Lansdorp, Steven J. M. Jones

Summary: Researchers have developed a method to determine the parent of origin for all human autosomes by integrating methylation-detecting nanopore sequencing with Strand-seq data. This method has the potential to improve the diagnosis and management of genetic diseases.

CELL GENOMICS (2023)

Article Genetics & Heredity

Two years of newborn screening for Duchenne muscular dystrophy as a part of the statewide Early Check research program in North Carolina

Katerina S. Kucera, Beth Lincoln Boyea, Brooke Migliore, Sarah Nelson Potter, Veronica R. Robles, Oksana Kutsa, Heidi Cope, Katherine C. Okoniewski, Anne Wheeler, Catherine W. Rehder, Edward C. Smith, Holly L. Peay

Summary: Screening for elevated CK-MM levels in dried blood spots is a feasible method to identify newborns with DMD. Including specific cutoffs, repeat testing, and genetic sequencing can improve the accuracy and sensitivity of screening.

GENETICS IN MEDICINE (2024)

Article Genetics & Heredity

Preparing for the unexpected: Recommendations for returning secondary findings in late-stage cancer care

Madeline Currey, Ilana Solomon, Sarah Mcgraw, Jenny Shen, Francisco Munoz, Ernesto Sosa, Vanessa Puello-Lozano, Sam Wing, Lisa Lopez, Michelle Afkhami, Janine Lobello, Szabolcs Szelinger, Stacy W. Gray

Summary: This study conducted qualitative interviews with cancer patients and providers to identify gaps in clinical care and propose care delivery solutions for the return of secondary germline findings. The responses of patients varied depending on the amount of pre-test counseling they received, and providers identified insufficient clinic time as a major barrier to pretest education. Online support tools and standardized pre-test education models were favored by providers. There were differing perspectives on how pre-test education should be integrated into clinical workflows, but agreement on the inclusion of differences between somatic and germline testing, likelihood of medically actionable findings, and the possibility of being referred to a genetics provider.

GENETICS IN MEDICINE (2024)

Article Genetics & Heredity

Genome sequencing detects a wide range of clinically relevant copy-number variants and other genomic alterations

Kiely N. James, Shimul Chowdhury, Yan Ding, Sergey Batalov, Kelly Watkins, Yong Hyun Kwon, Lucitia Van Der Kraan, Katarzyna Ellsworth, Stephen F. Kingsmore, Lucia Guidugli

Summary: This study used genome sequencing to detect a wide range of copy-number variants (CNVs) and other non-single nucleotide variant/indel variant types. These genetic alterations accounted for 15.8% of reported variants, with deletions being the most common type. The study also found that additional genetic tests were ordered in some cases, but failed to report the variants detected by genome sequencing.

GENETICS IN MEDICINE (2024)

Article Genetics & Heredity

Physician services and costs after disclosure of diagnostic sequencing results in the NYCKidSeq program

Asem Berkalieva, Nicole R. Kelly, Ashley Fisher, Samuel F. Hohmann, Monisha Sebastin, Miranda Di Biase, Katherine E. Bonini, Priya Marathe, Jacqueline A. Odgis, Sabrina A. Suckiel, Michelle A. Ramos, Rosamond Rhodes, Noura S. Abul-Husn, John M. Greally, Carol R. Horowitz, Melissa P. Wasserstein, Eimear E. Kenny, Bruce D. Gelb, Bart S. Ferket

Summary: The study aims to understand the effects of returning diagnostic sequencing results on clinical actions and economic outcomes for pediatric patients with suspected genetic disorders. The results showed that patients with positive findings were more likely to receive specialist consultation, but there were no significant increases in overall physician services and costs. More large-scale studies are needed to confirm these findings.

GENETICS IN MEDICINE (2024)

Article Genetics & Heredity

Incidence, prevalence, age at diagnosis, and mortality in individuals with 45,X/46,XY mosaicism: A population-based registry study

Kirstine Stochholm, Camilla Holmgard, Shanlee M. Davis, Claus H. Gravholt, Agnethe Berglund

Summary: This study assessed the incidence, prevalence, and age at diagnosis of individuals with 45,X/46,XY mosaicism and described the associated mortality pattern. The study found an increasing incidence of 45,X/46,XY mosaicism in males and a stable incidence in females. Males were diagnosed at an older age than females. Additionally, 45,X/46,XY mosaicism was associated with increased all-cause mortality.

GENETICS IN MEDICINE (2024)

Article Genetics & Heredity

DLG2 intragenic exonic deletions reinforce the link to neurodevelopmental disorders and suggest a potential association with congenital anomalies and dysmorphism

Yunjia Chen, Ender Karaca, Nathaniel H. Robin, Dana Goodloe, Ali Al-Beshri, S. Joy Dean, Anna C. E. Hurst, Andrew J. Carroll, Fady M. Mikhail

Summary: This study confirms the association between DLG2 intragenic deletions and neurodevelopmental disorders, supports the haploinsufficiency of the DLG2 gene, and suggests a potential association between these deletions and congenital anomalies and dysmorphism.

GENETICS IN MEDICINE (2024)